Anzeige
Mehr »
Sonntag, 29.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JUH2 | ISIN: PLSELVT00013 | Ticker-Symbol: 9Y4
Frankfurt
27.06.25 | 08:02
7,180 Euro
-0,83 % -0,060
Branche
Biotechnologie
Aktienmarkt
OSTEUROPA
1-Jahres-Chart
RYVU THERAPEUTICS SA Chart 1 Jahr
5-Tage-Chart
RYVU THERAPEUTICS SA 5-Tage-Chart
RealtimeGeldBriefZeit
7,0907,82028.06.

Aktuelle News zur RYVU THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
25.02.Polish biotech Ryvu waves goodbye to 30% of staff in focus on phase 3 blood cancer trials3
25.02.Ryvu Therapeutics announces strategic reorganization to extend the cash runway for the development of RVU120 and the preclinical pipeline247Cash runway is extended from Q1 to H2 2026 with approximately €46 million (PLN 192 million) in cash and other financial assets held by Ryvu as of February 23,...
► Artikel lesen
12.12.24Ryvu Therapeutics provides an update on RVU120 Phase II program344KRAKOW, Poland, Dec. 12, 2024 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies...
► Artikel lesen
05.12.24Ryvu Therapeutics Announces Dosing of the First Patient in the POTAMI-61 Phase II Study of RVU120 for the Treatment of Patients with Myelofibrosis (MF)169The primary goal of the study is to evaluate the safety and efficacy of RVU120 in patients with myelofibrosis (MF), both as a single agent and in combination with...
► Artikel lesen
07.11.24Ryvu Therapeutics Reports 2024 Q3 Financial Results and Provides Corporate Update231In Q1-Q3 2024, Ryvu recognized total operating revenues (including grants) of USD 18.6 million, compared to USD 11.9 million in Q1-Q3 2023. Ryvu reports an acceleration...
► Artikel lesen
RYVU THERAPEUTICS Aktie jetzt für 0€ handeln
19.09.24Ryvu Therapeutics Announces Dosing of the First Patient in the REMARK Phase II Study of RVU120 for the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)238Ryvu Therapeutics has announced the dosing of the first patient in the REMARK Phase II study of RVU120. The primary goal of the REMARK study is to evaluate the safety and efficacy of RVU120 in patients...
► Artikel lesen
12.09.24Ryvu Therapeutics Reports 2024 Half-Year Financial Results and Provides Corporate Update279The total operating revenues in H1 2024 amounted to USD 12.1 million and increased by USD 4.2 million compared to H1 2023. As of September, 5 2024, Ryvu's cash position was USD 65.3 million. Together...
► Artikel lesen
7 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1